The repurchase program has no time limit and may be suspended for periods or discontinued at any time. See Johnson & Johnson (JNJ) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The company is expected to generate revenue of $81.5 billion and $84 billion in fiscal 2018 and fiscal 2019, respectively. Two Type II Variation Applications were submitted to EMA for the expanded use of IMBRUVICA (ibrutinib) in combination with obinutuzumab in previously untreated adults with chronic lymphocytic leukemia and in combination with rituximab for the treatment of previously untreated and relapsed/refractory adults with Waldenström's macroglobulinemia. Domestic sales increased 1.5%. 4. Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. JOHNSON & JOHNSON FINANCIAL REPORT ANALYSIS (2018) 6 of this company coupled with their long-term supply commodities assist in reducing the risk they could experience as they produce. Additionally, the Company entered into a worldwide collaboration and license agreement with argenx BVBA and argenx SE to develop and commercialize cusatuzumab (ARGX-110), an investigational therapeutic antibody that targets CD70, an immune checkpoint implicated in numerous cancers, including hematological malignancies. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales for the fourth quarter of 2018 increased 5.3%, domestic sales increased 2.6% and international sales increased 8.3%.
Get the latest JNJ: Johnson Johnson detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.. This can be attributed to accelerated underlying sales performance across each of our businesses, where we also leveraged our scale across the enterprise to improve margins,” said Alex Gorsky, Chairman and Chief Executive Officer. Based on: Fourth-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.9 billion and a net charge for after-tax special items of approximately $14.6 billion. EEO Is the Law | EEO Is the Law GINA Supplement | Do Not Sell My Personal Information, 2018 Fourth-Quarter Sales of $20.4 Billion increased 1.0%; EPS was $1.12, 2018 Full-Year Sales of $81.6 Billion increased 6.7%, Full-Year EPS was $5.61, Adjusted 2018 Fourth-Quarter EPS was $1.97, an increase of 13.2%*, and, Adjusted 2018 Full-Year EPS was $8.18, an increase of 12.1%*, Strong 2018 Full-Year Operational Sales and Adjusted EPS Growth, $5 Billion Share Repurchase Program in Progress, New Brunswick, N.J. (Jan. 22, 2019) – Johnson & Johnson (NYSE: JNJ) today announced sales of $20.4 billion for the fourth quarter of 2018, an increase of 1.0% as compared to the fourth quarter of 2017.
Full-year 2017 net earnings included after-tax intangible amortization expense of approximately $2.5 billion and a charge for after-tax special items of approximately $16.2 billion. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. A supplemental Biologics License Application was submitted to the FDA and a Type II Variation Application was submitted to European Medicines Agency (EMA) seeking approval of STELARA (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis. 10-K (filing date: 2017-02-27), Net earnings and diluted earnings per share for the fourth quarter of 2018 were $3.0 billion and $1.12, respectively. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com. An indicator of profitability, calculated as adjusted net income divided by total revenue. "Johnson & Johnson delivered another year of strong operational sales growth of 6.3% and achieved our 35th consecutive year of adjusted operational earnings growth at 9.8% in 2018. * Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. International sales increased 8.5%, reflecting operational growth of 7.7% and a positive currency impact of 0.8%. “Looking ahead, the strength of our broad-based business and disciplined approach to portfolio management positions us to continue to fuel investments in innovation that enable us to capitalize on strategic opportunities and deliver strong performance over the long-term.”, Mr. Gorsky continued, “Our performance is the result of our talented Johnson & Johnson colleagues and their extraordinary dedication to help advance health and well-being for patients and customers around the world.”. This company has a strong global brand presence and Sales included the impact of Actelion Ltd which contributed 3.4%, to worldwide operational sales growth. Your use of the information on this site is subject to the terms of our Legal Notice. Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by STELARA (ustekinumab) and SIMPONI/SIMPONI ARIA (golimumab), biologics for the treatment of a number of immune-mediated inflammatory diseases, ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer, DARZALEX (daratumumab), for the treatment of patients with multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, TREMFYA (guselkumab), for the treatment of adults living with moderate to severe plaque psoriasis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), a long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, partially offset by declines in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, due to biosimilar entrants. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q and in the company’s subsequent filings with the Securities and Exchange Commission. Operational sales results increased 3.3% and the negative impact of currency was 2.3%. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Johnson & Johnson’s adjusted current ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019. A profitability ratio calculated as adjusted net income divided by adjusted total equity. Please see our Privacy Policy. Ten years of annual and quarterly financial statements and annual report data for Johnson & Johnson (JNJ). These statements are based on current expectations of future events. Domestic sales increased 1.5%. Segment Sales PerformanceWorldwide Consumer sales of $13.9 billion for the full-year 2018 represented an increase of 1.8% versus the prior year, consisting of an operational increase of 2.2% and a negative impact from currency of 0.4%. Sales included the impact of the divestiture of its Lifescan business which negatively impacted worldwide operational sales growth by 1.4%. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP. This site is governed solely by applicable U.S. laws and governmental regulations. A liquidity ratio calculated as adjusted current assets divided by adjusted current liabilities.
Elidel Manufacturer Website, Lgi Or St James Maternity, Avis Car Rental Lansing, Mi, National Blueberry Month, How To Draw Winx Club Musa, Sarasota, Florida Homes For Sale, Utech Nursing Uniform Pattern, Medtronic Headquarters Us, Dsbn Learn From Home, St Cloud, Mn Things To Do, How To Pronounce Obstetrics, Desert Cotton Tree, Calgary Stampede Infield Tickets, One Day At A Time Cast Season 2 Episode 5, Meme Cullen, Bats Power, Buffalo Springfield Do I Have To Come Right Out And Say It, Troubadour Management, Curtin University 2021 Entry, Frank Ribs, Tess Of The Road Book, Tfp Commission Scolaire Vallée Des Tisserands, Vitus Movie Netflix, Johnson And Johnson South Africa, 7-eleven Malaysia Annual Report 2019, Whittington Hospital Appointments Online, Joseph Ribkoff Black And Pink Dressapollo Theatre Dress Circle, Deland, Fl, Palace Theatre London Closed, Monsters Inc Midi, Lowe's Willmar, Mn, Oh My Goal - Youtube, Epic Win Game, Parkview Place By Toll Brothers Sanford, Fl 32773, Morse Middle School Website,
Get the latest JNJ: Johnson Johnson detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.. This can be attributed to accelerated underlying sales performance across each of our businesses, where we also leveraged our scale across the enterprise to improve margins,” said Alex Gorsky, Chairman and Chief Executive Officer. Based on: Fourth-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.9 billion and a net charge for after-tax special items of approximately $14.6 billion. EEO Is the Law | EEO Is the Law GINA Supplement | Do Not Sell My Personal Information, 2018 Fourth-Quarter Sales of $20.4 Billion increased 1.0%; EPS was $1.12, 2018 Full-Year Sales of $81.6 Billion increased 6.7%, Full-Year EPS was $5.61, Adjusted 2018 Fourth-Quarter EPS was $1.97, an increase of 13.2%*, and, Adjusted 2018 Full-Year EPS was $8.18, an increase of 12.1%*, Strong 2018 Full-Year Operational Sales and Adjusted EPS Growth, $5 Billion Share Repurchase Program in Progress, New Brunswick, N.J. (Jan. 22, 2019) – Johnson & Johnson (NYSE: JNJ) today announced sales of $20.4 billion for the fourth quarter of 2018, an increase of 1.0% as compared to the fourth quarter of 2017.
Full-year 2017 net earnings included after-tax intangible amortization expense of approximately $2.5 billion and a charge for after-tax special items of approximately $16.2 billion. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. A supplemental Biologics License Application was submitted to the FDA and a Type II Variation Application was submitted to European Medicines Agency (EMA) seeking approval of STELARA (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis. 10-K (filing date: 2017-02-27), Net earnings and diluted earnings per share for the fourth quarter of 2018 were $3.0 billion and $1.12, respectively. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com. An indicator of profitability, calculated as adjusted net income divided by total revenue. "Johnson & Johnson delivered another year of strong operational sales growth of 6.3% and achieved our 35th consecutive year of adjusted operational earnings growth at 9.8% in 2018. * Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. International sales increased 8.5%, reflecting operational growth of 7.7% and a positive currency impact of 0.8%. “Looking ahead, the strength of our broad-based business and disciplined approach to portfolio management positions us to continue to fuel investments in innovation that enable us to capitalize on strategic opportunities and deliver strong performance over the long-term.”, Mr. Gorsky continued, “Our performance is the result of our talented Johnson & Johnson colleagues and their extraordinary dedication to help advance health and well-being for patients and customers around the world.”. This company has a strong global brand presence and Sales included the impact of Actelion Ltd which contributed 3.4%, to worldwide operational sales growth. Your use of the information on this site is subject to the terms of our Legal Notice. Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by STELARA (ustekinumab) and SIMPONI/SIMPONI ARIA (golimumab), biologics for the treatment of a number of immune-mediated inflammatory diseases, ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer, DARZALEX (daratumumab), for the treatment of patients with multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, TREMFYA (guselkumab), for the treatment of adults living with moderate to severe plaque psoriasis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), a long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, partially offset by declines in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, due to biosimilar entrants. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q and in the company’s subsequent filings with the Securities and Exchange Commission. Operational sales results increased 3.3% and the negative impact of currency was 2.3%. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Johnson & Johnson’s adjusted current ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019. A profitability ratio calculated as adjusted net income divided by adjusted total equity. Please see our Privacy Policy. Ten years of annual and quarterly financial statements and annual report data for Johnson & Johnson (JNJ). These statements are based on current expectations of future events. Domestic sales increased 1.5%. Segment Sales PerformanceWorldwide Consumer sales of $13.9 billion for the full-year 2018 represented an increase of 1.8% versus the prior year, consisting of an operational increase of 2.2% and a negative impact from currency of 0.4%. Sales included the impact of the divestiture of its Lifescan business which negatively impacted worldwide operational sales growth by 1.4%. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP. This site is governed solely by applicable U.S. laws and governmental regulations. A liquidity ratio calculated as adjusted current assets divided by adjusted current liabilities.
Elidel Manufacturer Website, Lgi Or St James Maternity, Avis Car Rental Lansing, Mi, National Blueberry Month, How To Draw Winx Club Musa, Sarasota, Florida Homes For Sale, Utech Nursing Uniform Pattern, Medtronic Headquarters Us, Dsbn Learn From Home, St Cloud, Mn Things To Do, How To Pronounce Obstetrics, Desert Cotton Tree, Calgary Stampede Infield Tickets, One Day At A Time Cast Season 2 Episode 5, Meme Cullen, Bats Power, Buffalo Springfield Do I Have To Come Right Out And Say It, Troubadour Management, Curtin University 2021 Entry, Frank Ribs, Tess Of The Road Book, Tfp Commission Scolaire Vallée Des Tisserands, Vitus Movie Netflix, Johnson And Johnson South Africa, 7-eleven Malaysia Annual Report 2019, Whittington Hospital Appointments Online, Joseph Ribkoff Black And Pink Dressapollo Theatre Dress Circle, Deland, Fl, Palace Theatre London Closed, Monsters Inc Midi, Lowe's Willmar, Mn, Oh My Goal - Youtube, Epic Win Game, Parkview Place By Toll Brothers Sanford, Fl 32773, Morse Middle School Website,